RSP - On RAS drugs

Version vom 21. Juni 2020, 11:27 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

plus neprilysin
32282032 ä. Neprilysin inhibitor?angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients

aliskiren
32328234 2020. Does the direct renin inhibitor have a role to play in attenuating severity of the outbreak coronavirus disease 2019 (COVID-19)?

other papers

32283158 ä. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis
32344190 ä. Debate on Drugs That May Aggravate COVID-19
32363137 ä. Anti-RAS drugs and SARS-CoV-2 infection
32370986 ä. Renin-angiotensin-aldosterone system and COVID-19 infection
32286678 2020. Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19
32293003 ä. Hypertension, the renin?angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence
32215613 ä. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System?a Call for Epidemiologic Investigations
32339215 ä. Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for COVID-19
32332039 2020. Renin-angiotensin-aldosterone system inhibitors and COVID-19
32264922 2020. COVID-19 and the RAAS?a potential role for angiotensin II?
32213760 2020. Facts and reflections on COVID-19 and anti-hypertensives drugs
32303915 ä. Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
32323279 2020. Renin-Angiotensin-System (RAS) und COVID-19 - Zur Verordnung von RAS-Blockern
32250244 2020. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients
32324223 ä. Switching antihypertensive therapy in times of COVID-19: why we should wait for the evidence
32324222 ä. Switching to another antihypertensive effective drug when using ACEIs/ARBs to treat arterial hypertension during COVID-19
32286607 ä. Might renin?angiotensin system blockers play a role in the COVID-19 pandemic?
32266708 ä. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension
32274522 ä. Inhibitors of the renin-angiotensin system and SARS-CoV-2 infection
32231220 ä. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
32233755 2020. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
32275190 2020. Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non?COVID-19 Sepsis but Carries a Moderately Increased Risk of Death
32291526 2020. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
32341442 ä. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors?lessons from available evidence and insights into COVID-19
32305401 ä. Clinical Implications of SARS-Cov2 Interaction with Renin Angiotensin System
32233753 2020. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
32272142 ä. More evidence is urgently needed to confirm the relation between angiotensin-converting enzyme inhibitors and COVID-19
32227760 ä. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19
32304747 2020. Angiotensin receptor blockers and COVID-19
32246101 ä. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic
32358609 ä. The COVID-19 outbreak and the angiotensin-converting enzyme 2: too little or too much?
32292865 2020. COVID-19 and the Renin-Angiotensin System
32231328 ä. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
32203970 ä. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade
32311696 ä. Comment on ?Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade?
C7151242 ä. Controversy regarding ACE inhibitors / ARBs in Covid-19
32241880 2020. Drugs and the renin-angiotensin system in covid-19
32333398 2020. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance
32282224 2020. COVID-19 and Renin Angiotensin Blockers: Current Evidence and Recommendations
32302248 2020. ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection?
32302265 2020. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19
32286246 2020. COVID-19 infections are also affected by human ACE1 D/I polymorphism
32255491 2020. ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19
32320478 2020. Risks of ACE Inhibitor and ARB Usage in COVID-19: Evaluating the Evidence
32129518 ä. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics
32359088 2020. RAAS blockers in hypertension posing a higher risk towards the COVID-19
32295811 2020. EMA advice on renin-angiotensin system medicines during covid-19 pandemic
32329083 2020. (ang.)COVID-19 transmission through host cell directed network of GPCR
32356926 2020. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19
32304146 2020. Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections
32290680 2020. Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers
32310915 2020. ACE-inibitori, sartani e sindrome respiratoria acuta da coronavirus 2
32362297 ä. Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
32340044 2020. The ACE-2 in COVID-19: Foe or Friend?
32208987 2020. Renin-angiotensin system (RAS) blockers and the COVID-19 pandemic: at present there is no evidence to abandon RAS blockers
32367746 2020. ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective
32348166 2020. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study
32301766 ä. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2
32371817 2020. Angiotensin-converting enzyme-2 in SARS-CoV-2 infection: good or bad?
32371814 2020. Response to four comments on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic??
32371812 2020. COVID-19, hypertension and angiotensin receptor-blocking drugs
32371810 2020. Comment on ?Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic??
32351121 2020. Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder
32195824 2020. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
32374416 2020. ACE2 and prognosis of COVID-19 Insights from Bartter s and Gitelman s syndromes patients
32369211 2020. What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?
32330302 2020. Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19"
32221983 2020. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19
32266994 2020. Comment on "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19"
32369097 ä. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
32376099 ä. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
32324209 ä. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China
32242890 2020. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers

32356627 ä. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19
32356625 ä. Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19
32356628 ä. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19
32267499 ä. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease
32164092 2020. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia
32340096 2020. Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension
32283876 2020. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19
32189489 2020. ACE2 in the context of 2019-nCoV infection: friend or foe?

C7197241 2020. ACEI inhibitors and ARBs do not increase severity of COVID-19
C7183935 ä. Status of SARS-CoV-2 infection in patients on renal replacement therapy Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)?
32248854 ä. A potential protective role of losartan against coronavirus-induced lung damage
32414646 2020. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
32448641 ä. Bloqueantes del sistema renina-angiotensina e infeccion por COVID-19
32389847 2020. Urgent need for evaluating agonists of angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19
32332868 ä. Mechanisms by which angiotensin-receptor blockers increase ACE2 levels
32360010 2020. The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic
32268149 2020. An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
32376099 2020. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
32456945 ä. Supresion de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica
32266375 ä. Inquiring into Benefits of Independent Activation of Non-Classical Renin-Angiotensin System in the Clinical Prognosis and Reduction of COVID-19 mortality
32228222 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

32220710 2020. Renin-angiotensin system: The unexpected flaw inside the human immune system revealed by SARS-CoV-2
32034638 ä. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury